Heart failure and COPD – Review Article

Czech version

Authors: B. Novotná; V. Koblížek; O. Kudela
Authors‘ workplace: Plicní klinika, LF UK a FN Hradec Králové
Published in: Kardiol Rev Int Med 2014, 16(5): 348-351
Category: Cardiology Review

Overview

Chronic obstructive pulmonary disease (COPD) and heart failure are diseases with a high prevalence both in Europe and worldwide. Heart failure is often seen as a comorbidity in COPD patients, as they have similar risk factors, such as smoking, older age and systemic inflammation. Their similar clinical manifestation presents clinical challenges when recognizing one disease in the presence of the other. The treatment of heart failure in patients with COPD is often not satisfactory due to the fear of higher incidence of adverse effects.

Keywords:
COPD – heart failure – comorbidities – treatment

Sources

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated January 2014. [online] Available from: http:/ / www.goldcopd.org/ uploads/ users/ files/ GOLD_Report_2014_Jun11.pdf

2. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787– 1847. doi: 10.1093/ eurheartj/ ehs104.

3. Cífková R. Arterial hypertension as a public health issue in the Czech Republic. Blood Press Suppl 2005; 2: 25– 28.

4. van Deursen VM, Urso R, Laroche C et al. Co‑ morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103– 111. doi: 10.1002/ ejhf.30.

5. Saheb Sharif‑ Askari N, Syed Sulaiman SA, Saheb Sharif‑ Askari F et al. Hospitalized heart failure patients with preserved vs. reduced ejection fraction in Dubai, United Arab Emirates: a prospective study. Eur J Heart Fail 2014; 4: 454– 460. doi: 10.1002/ ejhf.51.

6. Matamis D, Tsagourias M, Papathanasiou A et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care 2014; 29: 315.e7– e14. doi: 10.1016/ j.jcrc.2013.11.011.

7. Güder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep 2014; 11: 337– 346. doi: 10.1007/ s11897‑ 014‑ 0212‑ x.

8. Theander K, Hasselgren M, Luhr K et al. Symptoms and impact of symptoms on function and health in patients with chronic obstructive pulmonary disease and chronic heart failure in primary health care. Int J Chron Obstruct Pulmon Dis 2014; 9: 785– 794. doi: 10.2147/ COPD.S62563.

9. Peters SP. When the chief complaint is (or should be) dyspnea in adults. J Allergy Clin Immunol Pract 2013; 1: 129– 136. doi: 10.1016/ j.jaip.2013.01.004.

10. Andrikopoulos G, Pastromas S, Kartalis A et al. Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study. Hellenic J Cardiol 2012; 53: 118– 126.

11. Ormiston TM, Salpeter SR. Beta‑blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence‑based practice. Heart Fail Monit 2003; 4: 45– 54.

12. Calder L, Tierney S, Jiang Y et al. Patient safety analysis of the ED care of patients with heart failure and COPD exacerbations: a multicenter prospective cohort study. Am J Emerg Med 2014; 32: 29– 35. doi: 10.1016/ j.ajem.2013.09.013.

13. Yao DK, Wang LX, Curran S et al. Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population. J Geriatr Cardiol 2011; 8: 88– 92. doi: 10.3724/ SP.J.1263.2011.00088.

14. Stefan MS, Rothberg MB, Priya A et al. Association between b‑blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012; 67: 977– 984. doi: 10.1136/ thoraxjnl‑ 2012‑ 201945.

15. Yoshihisa A, Takiguchi M, Shimizu T et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014. pii: S0914– 5087(14)00049– 5. doi: 10.1016/ j.jjcc.2014.02.003.

16. Maly M, Zvolsky M, Rozborilova E et al. Úmrtnost v České a Slovenské republice v roce 2011 a podíly respiračních nemocí. Stud Pneumol Phtiseol 2013, 79: 128–132.

17. Vondra V. Úmrtnost na CHOPN v letech 1996– 2005 se zdvojnásobila. Stud Pneumol Phtiseol 2007; 73: 75–77.

18. Institute of Medical Information Services. Tuberculosis and respiratory diseases 2011. [online] Available from: http:/ / www.uzis.cz/ katalog/

19. 2012 European Cardiovascular Disease Statistics. [online] Available from: http:/ / www.ehnheart.org/ cvd‑ statistics.html

20. Špinar J, Hradec J, Meluzín J et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007; 47: K5– K34.

21. Cleland JG, Swedberg K, Follath F et al. The Euro Heart Failure Survey Programme – a survey on the quality of care among patients with heart failure in Europe. Part I: patients characteristics and diagnosis. Eur Heart J 2003; 24: 442– 463.

22. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013; 34: 2795– 2803. doi: 10.1093/ eurheartj/ eht192.

23. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162: 237– 251. doi: 10.1016/ j.trsl.2013.05.001.

24. Miniati M, Monti S, Pavlickova I et al. Survival in COPD: Impact of Lung Dysfunction and Comorbidities. Medicine (Baltimore) 2014; 93: e76. doi: 10.1097/ MD.0000000000000076.

25. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 871– 888.

26. van Deursen VM, Damman K, van der Meer P et al. Co‑ morbidities in heart failure. Heart Fail Rev 2014; 19: 163– 172. doi: 10.1007/ s10741‑ 012‑ 9370‑ 7.

27. van Deursen VM, Urso R, Laroche C et al. Co‑ morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103– 111. doi: 10.1002/ ejhf.30.

28. Iacoviello M, Antoncecchi V. Heart failure in elderly: progress in clinical evaluation and therapeutic approach. J Geriatr Cardiol 2013; 10: 165– 177. doi: 10.3969/ j.issn.1671‑ 5411.2013.02.010.

29. Konecny T, Park JY, Somers KR et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014; 114: 272– 277. doi: 10.1016/ j.amjcard.2014.04.030.

30. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125: 669– 682.

31. Rahaghi FN, van Beek EJ, Washko GR. Cardiopulmonary coupling in chronic obstructive pulmonary disease: the role of imaging. J Thorac Imaging 2014; 29: 80– 91. doi: 10.1097/ RTI.0000000000000076.

32. Klzo L. Magnetická rezonance srdce. Lékařské listy 2004, 43: 14– 16.

33. Nishimura K, Nishimura T, Onishi K et al. Changes in plasma levels of B‑type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 155– 162. doi: 10.2147/ COPD.S55143.

34. Gariani K, Delabays A, Perneger TV et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly 2011; 141: w13298. doi: 10.4414/ smw.2011.13298.

35. Minasian AG, van den Elshout FJ, Dekhuijzen PN et al. Pulmonary function impairment in patients with chronic heart failure: lower limit of normal versus conventional cutoff values. Heart Lung 2014; 43: 311– 316. doi: 10.1016/ j.hrtlng.2014.03.011.

36. Magee MJ, Herbert MA, Roper KL et al. Pulmonary function tests overestimate chronic pulmonary disease in patients with severe aortic stenosis. Ann Thorac Surg 2013; 96: 1329– 1335. doi: 10.1016/ j.athoracsur.2013.04.123.

37. Minasian AG, van den Elshout FJ, Dekhuijzen PN et al. COPD in chronic heart failure: less common than previously thought? Heart Lung 2013; 42: 365– 371. doi: 10.1016/ j.hrtlng.2013.07.002.

38. Doos L, Roberts EO, Corp N et al. Multi‑drug therapy in chronic condition multimorbidity: a systematic review. Fam Pract 2014. pii: cmu056. [Epub]

39. Puente‑ Maestu L, Calle M, Ortega‑ González A et al. Multicentric study on the beta‑blocker use and relation with exacerbations in COPD. Respir Med 2014; 108: 737– 744. doi: 10.1016/ j.rmed.2014.02.009.

40. Lopez‑ Jimenez F, Simha V, Thomas RJ et al. A Summary and Critical Assessment of the 2013 ACC/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. Mayo Clin Proc 2014; 89: 1257– 1278. doi: 10.1016/ j.mayocp.2014.06.016.

41. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803– 869. doi: 10.1093/ eurjhf/ hfs105.

42. Spinar J, Spinarová L, Vítovec J et al. Srovnání amerických a evropských (českých doporučení pro diagnostiku a léčbu chronického srdečního selhání. Vnitr Lek 2014; 60: 366, 368– 374.

43. Yoo BS, Oh J, Hong BK et al. SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi‑center, retrospective, observational study. PLoS One 2014; 9: e86596. doi: 10.1371/ journal.pone.0086596.

44. Maggioni AP, Anker SD, Dahlström U et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long‑Term Registry. Eur J Heart Fail 2013; 15: 1173– 1184. doi: 10.1093/ eurjhf/ hft134.

45. Calder L, Tierney S, Jiang Y et al. Patient safety analysis of the ED care of patients with heart failure and COPD exacerbations: a multicenter prospective cohort study. Am J Emerg Med 2014; 32: 29– 35. doi: 10.1016/ j.ajem.2013.09.013.

46. Muth C, Kirchner H, van den Akker M et al. Current guidelines poorly address multimorbidity: pilot of the interaction matrix method. J Clin Epidemiol 2014; pii: S0895– 4356(14)00324– 2. doi: 10.1016/ j.jclinepi.2014.07.004.

47. Ege MR, Guray U, Guray Y, Yilmaz MB et al. Acute heart failure with accompanying chronic obstructive pulmonary disease: should we focus on beta blockers? Herz 2012; 37: 796– 800. doi: 10.1007/ s00059‑ 012‑ 3641‑ x.

48. Mosalpuria K, Agarwal SK, Yaemsiri S et al. Outpatient management of heart failure in the United States, 2006– 2008. Tex Heart Inst J 2014; 41: 253– 261. doi: 10.14503/ THIJ‑ 12‑ 2947.

49. Angeloni E, Melina G, Roscitano A et al. β‑ Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg 2013; 95: 525– 531. doi: 10.1016/ j.athoracsur.2012.07.080.

50. Mentz RJ, Wojdyla D, Fiuzat M et al. Association of beta‑blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE‑ HF). Am J Cardiol 2013; 111: 582– 587. doi: 10.1016/ j.amjcard.2012.10.041.

51. Farland MZ, Peters CJ, Williams JD et al. b‑ Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother 2013; 47: 651– 656. doi: 10.1345/ aph.1R600.

52. Kargin F, Takir HB, Salturk C et al. The safety of beta‑blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit. Multidiscip Respir Med 2014; 9: 8. doi: 10.1186/ 2049‑ 6958‑ 9‑ 8.

53. Ni Y, Shi G, Wan H. Use of cardioselective β‑blockers in patients with chronic obstructive pulmonary disease: a meta‑analysis of randomized, placebo‑ controlled, blinded trials. J Int Med Res 2012; 40: 2051– 2065.

54. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta‑blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; CD003566.

55. Lee DS, Markwardt S, McAvay GJ et al. Effect of β‑blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care 2014; 52: Suppl 3: S45– S51. doi: 10.1097/ MLR.0000000000000035.

56. Hawkins NM, Jhund PS, Simpson CR et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010; 12: 17– 24. doi: 10.1093/ eurjhf/ hfp160.

57. Cazzola M, Ciaprini C, Page CP et al. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opin Ther Targets 2007; 11: 1273– 1286.

58. Cazzola M, Matera MG, Rogliani P et al. Treating systemic effects of COPD. Trends Pharmacol Sci 2007; 28: 544– 550.

59. Gershon A, Croxford R, Calzavara A et al. Cardiovascular safety of inhaled long‑acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013; 173: 1175– 1185. doi: 10.1001/ jamainternmed.2013.1016.

60. Verhamme KM, Afonso AS, van Noord C et al. Tiotropium Handihaler and the risk of cardio‑ or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther 2012; 25: 19– 26. doi: 10.1016/ j.pupt.2011.10.004.

61. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med 2011; 40: 135– 145. doi: 10.1016/ j.jemermed.2007.11.056.

62. Mentz RJ, Fiuzat M, Kraft M et al. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? J Card Fail 2012; 18: 413– 422. doi: 10.1016/ j.cardfail.2012.02.002.

63. Burgel PR, Paillasseur JL, Dusser D et al. Tiotropium might improve survival in subjects with COPD at hight risk of mortality. Respir Res 2014; 15: 64. doi: 10.1186/ 1465‑ 9921‑ 15‑ 64.

64. Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491– 1501. doi: 10.1056/ NEJMoa1303342.

65. Fisher K, Stefan M, Darling C et al. Impact of COPD on the Mortality and Treatment of Patients Hospitalized with Acute Decompensated Heart Failure (The Worcester Heart Failure Study). Chest 2014. doi: 10.1378/ chest.14‑ 0607.

66. Pocock SJ, Ariti CA, McMurray JJ et al. Meta‑Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404– 1413. doi: 10.1093/ eurheartj/ ehs337.